Premium
Inhibitors of lipogenic enzymes as a potential therapy against cancer
Author(s) -
Montesdeoca Nicolás,
López Marta,
Ariza Xavier,
Herrero Laura,
Makowski Kamil
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.202000705r
Subject(s) - lipid metabolism , cancer , cancer cell , cell growth , enzyme , fatty acid synthesis , cancer therapy , cancer research , metabolic pathway , fatty acid metabolism , biochemistry , cell , lipogenesis , biology , metabolism , chemistry , genetics
Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs.